Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
It's Time To Go To Cash For The Next 7 Years - 1-Year Update
07:41pm, Thursday, 20'th Jan 2022 Seeking Alpha
The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.
Pfizer''s Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
04:42pm, Wednesday, 19'th Jan 2022 Seeking AlphaPfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
11:42am, Wednesday, 19'th Jan 2022
Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo
01:16pm, Monday, 17'th Jan 2022 Zacks Investment Research
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Is Beam Therapeutics a Good Stock to Buy Now?
11:47am, Sunday, 16'th Jan 2022 The Motley Fool
A new partnership with Pfizer will inject a lot of cash into Beam Therapeutics' coffers.
Is Beam Therapeutics a Good Stock to Buy Now?
06:47am, Sunday, 16'th Jan 2022
A new partnership with Pfizer will inject a lot of cash into Beam Therapeutics' coffers.
Pharma Stock Roundup: PFE's Research Deal With BEAM & Other Updates
03:07pm, Friday, 14'th Jan 2022 Zacks Investment Research
Pfizer (PFE) inks research collaboration with Beam Therapeutics. Merck's (MRK) Keytruda improves survival in adjuvant lung cancer
Why Editas Medicine Stock Is Tumbling This Week
10:24pm, Thursday, 13'th Jan 2022 The Motley Fool
The overall sell-off of biotech stocks appears to be the main culprit.
Pfizer (PFE) Partners Beam Therapeutics for Rare Disease Drugs
03:31pm, Tuesday, 11'th Jan 2022 Zacks Investment Research
Pfizer (PFE) collaborates with Beam Therapeutics (BEAM) to advance the next generation of gene-editing therapies.
Pfizer, Beam Announce Up To $1.35 Bln, Exclusive Multi-year, Research Collaboration
11:38am, Monday, 10'th Jan 2022 Business Insider Markets
(RTTNews) - Pharma major Pfizer Inc. (PFE), and Beam Therapeutics Inc. (BEAM), a company focused on genetic medicines through base editing, entered into an exclusive four-year research collaboration aimed at vivo base editing programs for three targets for rare genetic diseases of the liver, muscle, and central nervous system. According to
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
11:30am, Monday, 10'th Jan 2022 Investor''s Business Daily
Pfizer is entering the CRISPR space through a $1.35 billion deal with Beam, the companies said Monday, in a deal sure to spark Beam stock.
Pfizer joins Beam Therapeutics to develop rare disease therapies By Reuters
11:29am, Monday, 10'th Jan 2022 Investing.com
Pfizer joins Beam Therapeutics to develop rare disease therapies
Beam gains 8% on collaboration with Pfizer to advance in vivo programs for rare diseases
11:19am, Monday, 10'th Jan 2022 Seeking Alpha
Beam Therapeutics (BEAM) perks up 8% premarket after announcing an exclusive four-year research collaboration with Pfizer (PFE), focused on in vivo base editing programs for three
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
11:00am, Monday, 10'th Jan 2022 GlobeNewswire Inc.
NEW YORK and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines thr
Pfizer Bets Big On mRNA: New Deals Include $1.3 Billion Collaboration With Beam
10:05am, Monday, 10'th Jan 2022
The string of new deals announced Monday include a potential deal with gene editing specialist Beam Therapeutics, including a $300 million upfront payment.
